ESG Report

Overview

The report presents Xinhua Pharmaceutical's ESG performance for 2023 across governance, product responsibility, environmental management, employee welfare and community contribution. The Board is identified as the highest responsible, decision-making and supervisory body for ESG matters. The company reported 18,956 tCO 2e of Scope I emissions and 241,687 tCO 2e of Scope II emissions, 7,104 employees and zero work-related deaths. It also reported 44 patents granted, RMB 405,870 thousand in R&D investment and 181,862 hours of employee training.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language: English
Pages
File size

Standards

Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services